Buddy Balloon to Deliver a Percutaneous Aortic Valve Device: A Percutaneous Shoehorn?
Division of Cardiology, University of Turin, S. Giovanni Battista Molinette Hospital, Turin, Italy.Catheterization and Cardiovascular Interventions (Impact Factor: 2.11). 11/2009; 74(5):805-7. DOI: 10.1002/ccd.22118
Percutaneous aortic valve replacement is performed with increasing frequency in patients with severe aortic stenosis at prohibitive surgical risk. Currently available devices are however in their early development stage, and are thus quite bulky with a large profile, with ensuing difficulties in delivery of the device through a stenotic aortic valve. We report hereby a case in which we employed a buddy wire and balloon technique as a "shoehorn" to enable accurate delivery of a balloon-expandable aortic valve prosthesis from the transfemoral route.
Article: A Thriller With a Happy EndCatheterization and Cardiovascular Interventions 11/2009; 74(5):808-10. DOI:10.1002/ccd.22270 · 2.11 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Surgical aortic valve replacement (SAVR) is the only treatment known to improve symptoms and survival in patients with severe, symptomatic aortic stenosis. Perioperative mortality, however, is high among many patients for whom SAVR may be indicated. Percutaneous heart valve replacement (PHVR) is an emerging, catheter-based technology that allows for implantation of a prosthetic valve without open heart surgery. This review describes the available literature on PHVR for aortic stenosis, which comprised 84 published reports representing 76 distinct studies and 2375 unique patients. Successful implantation was achieved in 94% of patients; 30-day survival was 89%. Differences between patients undergoing PHVR and those typically selected for SAVR make full interpretation of these results difficult. A large, multicenter, randomized, controlled trial comparing PHVR with SAVR or medical management was recently completed, with initial results expected in September 2010. Pending publication of findings from that trial, the available evidence is inadequate to determine the most appropriate clinical role of PHVR or the specific patient populations for whom it might eventually be indicated.Annals of internal medicine 09/2010; 153(5):314-24. DOI:10.1059/0003-4819-153-5-201009070-00267 · 17.81 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Transcatheter aortic valve implantation has risen exponentially as a treatment modality for severe aortic stenosis in patients considered to be at high risk for or inoperable by conventional surgical aortic valve replacement. It has shown both survival and quality of life benefit in a randomized comparison to conservative (palliative) therapy in nonoperative candidates. Fundamental to its success is appropriate patient selection and a rigorous attention to procedural steps. In this article we will discuss the key issues pertaining to each of these factors.Future Cardiology 07/2011; 7(4):499-509. DOI:10.2217/fca.11.26
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.